{"filing":{"accession_number":"0001104659-26-089655","cik":"0001567892","ticker":null,"company_name":"Keenova Therapeutics plc","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-31","primary_document":"tm2621903d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465926089655/tm2621903d1_8k.htm"},"events":[{"id":23304,"run_id":21073,"accession_number":"0001104659-26-089655","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses the closing of a material sale of two business units (Percocet and Endocet) to Par Health, Inc. for approximately $250 million in total consideration ($25 million upfront plus five years of earnout payments). This constitutes a material disposition/divestiture that fundamentally alters the company's business scope—the company explicitly states it will \"no longer market, manufacture or distribute opioid products\" following completion. This is a completed M\u0026A transaction requiring disclosure under Item 1.02 or 2.01 standards, disclosed here under Item 8.01.","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23501,"accession_number":"0001104659-26-089655","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the closing of a material sale of two business units (Percocet and Endocet) to Par Health, Inc. for approximately $250 million in total consideration ($25 million upfront plus five years of earnout payments). This constitutes a material disposition/divestiture that fundamentally alters the company's business scope—the company explicitly states it will \"no longer market, manufacture or distribute opioid products\" following completion. This is a completed M\u0026A transaction requiring disclosure under Item 1.02 or 2.01 standards, disclosed here under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:18:32.591075+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23501,"accession_number":"0001104659-26-089655","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the closing of a material sale of two business units (Percocet and Endocet) to Par Health, Inc. for approximately $250 million in total consideration ($25 million upfront plus five years of earnout payments). This constitutes a material disposition/divestiture that fundamentally alters the company's business scope—the company explicitly states it will \"no longer market, manufacture or distribute opioid products\" following completion. This is a completed M\u0026A transaction requiring disclosure under Item 1.02 or 2.01 standards, disclosed here under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:18:32.591075+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-08-03"}]}